Boehringer Ingelheim, Propeller Health partner to improve Respimat inhaler adherence

Boehringer Ingelheim and Propeller Health announced Wednesday a partnership that will use the latter\'s digital health tools and services to improve adherence in people with asthma and chronic obstructive pulmonary disease (COPD) who are using Boehringer Ingelheim\'s Respimat inhaler. David Van Sickle, CEO of Propeller Health, remarked "together, we believe that digital tools can complement the use of respiratory medications and encourage more appropriate and effective management of chronic respiratory disease."

Under the partnership, patients with asthma and COPD, who are being treated with a Boehringer Ingelheim medication via the Respimat inhaler, can enroll at select US health systems in a programme, which is designed to determine how Propeller Health\'s health technology platform for the device effects adherence rates and patient engagement. According to the companies, the technology, which features inhaler sensors, apps, analytics, personal feedback and education, passively tracks how and when a patient uses their inhaled drugs and can send alerts to patients and caregivers.

Last year, the FDA granted 510(k) clearance to market Propeller\'s health technology platform in association with the Respimat inhaler. The technology also gained FDA 510(k) clearance for use with GlaxoSmithKline\'s Diskus dry powder inhaler in 2015, with the companies later entering a deal to develop and manufacture a custom sensor for the drugmaker\'s Ellipta dry powder inhaler.

To read more Top Story articles, click here.